JournalsHub
.online
Find My Journal
MO

Marion Ott

Independent Researcher

ORCID 0000-0001-5199-4664
130
Publications
3,602
Citations
21
H-Index
30
i10-Index
1.78
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

129 total

Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. OA

Marina Y. Konopleva, Monique Dail, N. Daver, Jacqueline S. Garcia, B. Jonas - Clinical Lymphoma, Myeloma & Leukemia, 2024
Cited by 6 Semantic Scholar

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial PDF

Naval Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen Yee et al. - Blood, 2022
Cited by 97 OpenAlex

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial PDF

Marina Konopleva, Christoph Röllig, Jamie Cavenagh, Dries Deeren, Larisa Girshova et al. - Blood Advances, 2022
Cited by 68 OpenAlex

Economic Games: An Introduction and Guide for Research PDF

Isabel Thielmann, Robert Böhm, Marion Ott, Benjamin E. Hilbig - Collabra Psychology, 2021
Cited by 110 OpenAlex

MDM2 inhibition: an important step forward in cancer therapy

Marina Konopleva, Giovanni Martinelli, Naval Daver, Cristina Papayannidis, Andrew H. Wei et al. - Leukemia, 2020
Cited by 371 OpenAlex

Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆

Karen Yee, Cristina Papayannidis, Norbert Vey, Michael Dickinson, Kevin R. Kelly et al. - Leukemia Research, 2020
Cited by 45 OpenAlex

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy OA

N. Daver, Jacqueline S. Garcia, B. Jonas, K. Kelly, S. Assouline - Blood, 2019
Cited by 32 Semantic Scholar

MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.

P. Montesinos, J. Esteve, M. Konopleva, G. Martinelli, O. Ottmann - Journal of Clinical Oncology, 2019
Cited by 7 Semantic Scholar

Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

N. Daver, D. Pollyea, Jacqueline S. Garcia, B. Jonas, K. Yee - Blood, 2018
Cited by 24 Semantic Scholar

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. OA

S. Temam, J. Spicer, F. Farzaneh, J. Soria, D. Oppenheim - Unknown Venue, 2017
Cited by 5 Semantic Scholar

Research Topics

Sociology and Education Studies (21) Auction Theory and Applications (21) Experimental Behavioral Economics Studies (18) Consumer Market Behavior and Pricing (11) Virus-based gene therapy research (10)

Affiliations

Karlsruhe Institute of Technology
DE 2015 - 2006
Goethe University Frankfurt
DE 2018 - 2004
Roche (Switzerland)
CH 2024 - 2012
University of Minnesota
US 2025 - 2025
Centre for European Economic Research
DE 2025 - 2017

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now